Drug Profile
CP 99243
Latest Information Update: 17 Jan 2007
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Jul 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 18 May 1995 Preclinical development for Bacterial infections in USA (Unknown route)